From: Dealing with heterogeneity of treatment effects: is the literature up to the challenge?
Predict HTE analysis | |
---|---|
Condition | OR (95% CI)* |
Journal of publication | † |
BMJ | 1.00 [reference] |
Annals | 4.22 (1.18–15.08) |
JAMA | 4.40 (1.43–13.53) |
Lancet | 1.44 (0.55–3.77) |
NEJM | 2.36 (0.85–6.56) |
Year of publication | |
2004 | 1.00 [reference] |
1999 | 0.88 (0.47–1.66) |
1994 | 0.83 (0.41–1.67) |
Medical condition under study | |
Other | 1.00 [reference] |
Cardiovascular | 1.07 (0.50–2.32) |
Infectious disease | 1.38 (0.66–2.89) |
Cancer | 1.13 (0.47–2.71) |
Psychiatry/Neurology | 2.85 (0.91–8.92) |
First author's study region | |
Other | 1.00 [reference] |
North America | 1.23 (0.67–2.29) |
Sample size | ‡ |
Quintile 1 (median = 37) | 1.00 [reference] |
Quintile 2 (median = 124) | 0.72 (0.24–2.14) |
Quintile 3 (median = 263) | 4.17 (1.62–10.74) |
Quintile 4 (median = 549) | 3.08 (1.20–7.91) |
Quintile 5 (median = 1560) | 7.55 (2.95–19.33) |